The content on this page was provided by an independent third party and syndicated by XPR Media. Members of the editorial and news staff of the USA TODAY Network were not involved in the creation of this content.

UTILITY Therapeutics Announces Acquisition by Alembic Pharmaceuticals Inc.

  • Alembic to expand their U.S. commercial portfolio with FDA-approved PIVYA for the treatment of women with uncomplicated urinary tract infections

  • PIVYA expected to be available in the U.S. in the 4th quarter of 2025.

LONDON, UK / ACCESS Newswire / July 3, 2025 / UTILITY therapeutics Ltd. (UTILITY), a biotechnology company focused on the development of PIVYA (pivmecillinam 185 mg tablets), a penicillin class antibacterial approved by the U.S. Food and Drug Administration (FDA) for the treatment of uncomplicated urinary tract infection (uUTI), today announced that it has been acquired by Alembic Pharmaceuticals, Inc. (Alembic).

PIVYA marked the first antibiotic in approximately 20 years to earn FDA approval for uUTI, a common bacterial infection that afflicts millions of women annually. The FDA approved PIVYA in April 2024 for use in female patients 18 years of age and older with uUTI caused by susceptible isolates of Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus. PIVYA has a unique mechanism of action that targets the cell wall of gram-negative bacteria.

Additional U.S. prescribing information about PIVYA can be found at www.pivya.com.

“We are thrilled that Alembic Pharmaceuticals understands the clinical and commercial value of PIVYA and will bring this proven treatment to female patients in need across the U.S.,” said Tom Hadley, President and CEO of UTILITY therapeutics. “With current therapies failing and the armament of uUTI antibiotics perilously thin, PIVYA provides U.S. clinicians with a new and effective treatment option that has a long safety record. We are grateful for the support of our Board of Directors and investors, including the AMR Action Fund, whose collective support was instrumental in helping us obtain FDA approval for PIVYA.”

The UTILITY therapeutics Ltd. Board of Directors and Observers includes:

  • Alan S. Roemer, MBA, MPH, Chairman of the Board

  • Morten Sommer, PhD, Co-Founder

  • Rasmus Toft-Kehler, PhD, Co-Founder

  • Andrew Davis, Independent Director

  • Larry Edwards, Independent Director

  • Thomas Hadley, President & CEO

  • Henry Skinner, PhD, MJur, MBA, AMR Action Fund

  • Tero Wennberg, PhD, Observer, LEO Pharma

  • Henni-Karoliina Ropponen, PhD, Observer, AMR Action Fund

“The acquisition of UTILITY and the commercialization of PIVYA are important steps in Alembic’s strategic goal to provide branded pharmaceutical products to the U.S. healthcare market,” said Craig Salmon, President of Alembic Pharmaceuticals, Inc. “PIVYA will further enhance Alembic’s ability to build long-term value by combining global research, regulatory, and manufacturing strengths with a sharpened focus on specialty segments. Alembic plans to make PIVYA available in the U.S. in the 4th quarter of 2025.”

“I am excited to see Alembic drive the commercialization of PIVYA, which is uniquely positioned to help millions of American women with urinary tract infections,” said Dr. Morten Sommer, Professor of microbiology at the Technical University of Denmark, and co-founder and board member of UTILITY therapeutics. “With a novel mechanism of action, not previously deployed in the U.S., PIVYA can become a cornerstone of the treatment of urinary tract infections based on its first-line positioning in the Infectious Disease Society of America treatment guidelines. On behalf of the co-founders, investors, and Board of Directors, we are excited that PIVYA will help address the societal impact of the uUTI disease burden in women.”

About PIVYA (pivmecillinam oral tablets 185mg)

PIVYA, an oral prodrug of mecillinam, is a penicillin class antibacterial indicated for the treatment of female patients 18 years of age and older with uncomplicated urinary tract infections (uUTI) caused by susceptible isolates of Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus.

Mecillinam demonstrated in vitro activity against Enterobacterales in the presence of some beta-lactamases and extended-spectrum beta-lactamases (ESBL) of the following groups: CTX-M, SHV, TEM, AmpC. The inhibitory action of mecillinam on PBP-2 results in low cross-resistance with certain beta-lactams. The frequency of resistance to mecillinam in E. coli range from
8×10-8 to 2×10-5 when exposed to 32-256 times MIC.

PIVYA has been proven safe and effective in three clinical trials with the most common Adverse Reactions Occurring in ≥1% of Patients Receiving PIVYA (Adjusted for Study Size); Nausea (4.3%), Diarrhea (2.1%), Vulvovaginal candidiasis (1.8%), Genital pruritus (1.8%), and Headache (1.4%).

PIVYA demonstrated strong response in three controlled clinical trials comparing different PIVYA dosing regimens to placebo (Trial 1), to another oral antibacterial drug (Trial 2), or to ibuprofen (Trial 4) evaluated the efficacy of pivmecillinam for the treatment of uUTI. Efficacy was assessed in the Microbiological Intent-to-Treat (micro-ITT) population which included all randomized subjects with a positive baseline urine culture defined as ≥105 colony-forming-units (CFU)/mL of a uropathogen where CFU count was available and no more than 2 species of microorganisms, regardless of colony count, and no baseline pathogen was non-susceptible to the active comparator. The composite response rates (composite endpoint of clinical cure and microbiological response), as well as clinical cure and microbiological response rates of the recommended 185 mg three times daily dosing regimen.

Composite Response Rates (Clinical Cure and Microbiological Response) at TOC in the uUTI trials (Micro ITT Population)

Composite Response Rates

(Clinical Cure and Microbiological Response)

Trial 1

PIVYA

N=137,

n (%)

Placebo

N=134,

n(%)

Difference

(95% CI)

85 (62)

14 (10)

52 (41,62)

Trial 2

PIVYA

N=127,

n (%)

Cephalexin

N=132

n(%)

91 (72)

100 (76)

-4(-16, +7)

Trial 4

PIVYA

N=105,

n (%)

Ibuprofen

N=119

n(%)

69 (66)

26 (22)

44 (31, 57)

Clinical Cure Rates (Micro-ITT Population)

Clinical Cure Rates

Trial 1

PIVYA

N=137,

n (%)

Placebo

N=134,

n(%)

Treatment

Difference

(95% CI)

87 (64)

31 (23)

40 (29, 52)

Trial 2

PIVYA

N=127,

n (%)

Cephalexin

N=132

n(%)

105 (83)

112 (85)

-2 (-12, +8)

Trial 4

PIVYA

N=105,

n (%)

Ibuprofen

N=119

n(%)

81 (77)

45 (38)

39 (27, 52)

Microbiological Response Rates (Micro-ITT Population)

Microbiological Response Rates

Trial 1

PIVYA

N=137,

n (%)

Placebo

N=134,

n(%)

Treatment

Difference

(95% CI)

119 (87)

35 (26)

61 (51,71)

Trial 2

PIVYA

N=127,

n (%)

Cephalexin

N=132

n(%)

97 (76)

106 (80)

-4 (-15, +7)

Trial 4

PIVYA

N=105,

n (%)

Ibuprofen

N=119

n(%)

78 (74)

64 (54)

  1. 7, 34)

Contraindications

  • Serious hypersensitivity reactions (e.g., anaphylaxis or Stevens-Johnson syndrome) to PIVYA or to other beta-lactam antibacterial drugs (e.g., penicillins and cephalosporins).

  • Primary or secondary carnitine deficiency resulting from inherited disorders of mitochondrial fatty acid oxidation and carnitine metabolism such as carnitine transporter defect or other inborn errors of metabolism (e.g., methylmalonic aciduria, or propionic academia).

  • Acute porphyria.

Warnings and precautions

  • Hypersensitivity Reactions: Serious hypersensitivity reactions including anaphylaxis have been reported in patients receiving PIVYA. If hypersensitivity reactions occur, discontinue treatment with PIVYA and institute appropriate therapy.

  • Severe Cutaneous Adverse Reactions (SCAR): Acute Generalized Exanthematous Pustulosis (AGEP), Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) have been reported with PIVYA. Monitor closely and discontinue PIVYA at the first signs or symptoms of SCAR or other signs of hypersensitivity.

  • Carnitine Depletion: In patients at risk for reductions in serum carnitine, e.g., significant renal impairment or decreased muscle mass, consider alternative antibacterial therapies. PIVYA is not recommended when prolonged antibacterial treatment is necessary. Avoid concurrent treatment with valproic acid, valproate or other pivalate-generating drugs due to increased risk of carnitine depletion.

  • Clostridioides difficile-Associated Diarrhea (CDAD): This has been reported with nearly all systemic antibacterial agents, including PIVYA. Evaluate if diarrhea occurs.

  • Interference with Newborn Screening Test: Treatment of a pregnant individual with PIVYA prior to delivery may cause a false positive test for isovaleric acidemia in the newborn as part of newborn screening. Prompt follow-up of a positive newborn screening result for isovaleric acidemia is recommended.

About UTILITY therapeutics Ltd.

UTILITY has exclusive U.S. commercial rights to two European-approved antibiotics, pivmecillinam and mecillinam, for the treatment of urinary tract infections (UTI). Pivmecillinam is an oral prodrug of mecillinam that has been approved by the FDA for the treatment of women with uncomplicated urinary tract infections. PIVYA has a unique mechanism of action for infections caused by Gram-negative bacteria, including extended-spectrum beta-lactamases. Mecillinam, an intravenous (IV) formulation, may be developed as a first-line therapy for complicated UTI (cUTI) in the hospital setting.

For more information, contact

David Cobb, Alembic Pharmaceuticals
david.cobb@alembicusa.com
908-552-583

SOURCE: Utility Therapeutics Ltd.

View the original press release on ACCESS Newswire

Information contained on this page is provided by an independent third-party content provider. XPRMedia and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@xpr.media

Unusual Machines Expands Leadership Team with Appointment of Tim Manton as Corporate Controller

Unusual Machines Expands Leadership Team with Appointment of Tim Manton as Corporate Controller

New hire supports operational scale-up and financial infrastructure as company ramps U.S. motor manufacturing ORLANDO, FLORIDA / ACCESS Newswire / July 9, 2025 / Unusual…

July 9, 2025

LAWSUIT: Pennsylvania Jury Awards $5.6M to Parents of Brain Damaged Child After Botched Birth and Invasion of Privacy

LAWSUIT: Pennsylvania Jury Awards $5.6M to Parents of Brain Damaged Child After Botched Birth and Invasion of Privacy

PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / July 9, 2025 / A Pennsylvania jury has awarded $5.6 million to the family of a child left debilitated…

July 9, 2025

Step Into the Smurfs’ World With Goose Creek’s New Candle Collection

Step Into the Smurfs’ World With Goose Creek’s New Candle Collection

Eight enchanting fragrances inspired by the iconic characters and cozy forest village. LIBERTY, KENTUCKY / ACCESS Newswire / July 9, 2025 / Goose Creek is…

July 9, 2025

Interactive Strength Inc. (Nasdaq: TRNR) Receives “Buy” Rating and $15 Price Target in Maxim Group Research Initiation

Interactive Strength Inc. (Nasdaq: TRNR) Receives “Buy” Rating and $15 Price Target in Maxim Group Research Initiation

First comprehensive sell-side report on TRNR cites more than 800% growth in expected 2025 revenue Valuation driven by stock-for-stock M&A model and potential crypto-treasury upside…

July 9, 2025

Certidox Adds AI-Powered QR Code Analysis to Free App for Document and Link Authentication

Certidox Adds AI-Powered QR Code Analysis to Free App for Document and Link Authentication

Certidox releases a major update to its free mobile app, adding AI-powered QR code analysis to detect phishing and fraud. The platform lets users instantly…

July 9, 2025

Preston Spire Taps Dustin Black to Supercharge “Good Wins” Creative Philosophy

Preston Spire Taps Dustin Black to Supercharge “Good Wins” Creative Philosophy

25-Year Industry Veteran to Guide Agency Through AI Evolution with “Culture of Curiosity” and Collaborative Leadership MINNEAPOLIS, MN / ACCESS Newswire / July 9, 2025…

July 9, 2025

Tidal Wave Auto Spa Continues Growth in Florida With Spring Hill Location Opening

Tidal Wave Auto Spa Continues Growth in Florida With Spring Hill Location Opening

Top Four Conveyor Car Wash Company Celebrates Grand Opening with Free Washes THOMASTON, GEORGIA / ACCESS Newswire / July 9, 2025 / Tidal Wave Auto…

July 9, 2025

Locally Owned, Physician-Led: A New Standard in Mobile Wound Care for South Carolina

Locally Owned, Physician-Led: A New Standard in Mobile Wound Care for South Carolina

Skip the Clinic – New Mobile Wound Care Service Offers Cutting-Edge Treatment at Home GREENVILLE, SOUTH CAROLINA / ACCESS Newswire / July 9, 2025 /…

July 9, 2025

Rivers are Life Highlights River Conservation at Wildlands 2025

Rivers are Life Highlights River Conservation at Wildlands 2025

Organization hosts river cleanup to support river conservation and awareness BIG SKY, MT / ACCESS Newswire / July 9, 2025 / Rivers are Life, a…

July 9, 2025

Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement

Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement

Early positive consumer testimonials from initial Company product sampling Sublingual nano technology delivers caffeine rapidly to the bloodstream, bringing its unique benefits to the pre-workout…

July 9, 2025

Augmentus Raises $11M to Scale Physical AI for High-Mix, Complex Robotic Surface Finishing and Welding

Augmentus Raises $11M to Scale Physical AI for High-Mix, Complex Robotic Surface Finishing and Welding

SINGAPORE, SG / ACCESS Newswire / July 9, 2025 / Augmentus, the developer of an intelligent no-code robotics solution, announced today that it has raised…

July 9, 2025

Crypto Tax Enforcement Is Back – Clear Start Tax Urges Traders to Avoid Costly Mistakes and Stay Compliant

Crypto Tax Enforcement Is Back – Clear Start Tax Urges Traders to Avoid Costly Mistakes and Stay Compliant

IRS letters targeting digital asset holders are on the rise – Clear Start Tax outlines what crypto traders need to know to protect themselves. IRVINE,…

July 9, 2025

Ahead of World IVF Day, HRC Fertility Launches Innovative Clinical Trial with Gameto for More Approachable IVF

Ahead of World IVF Day, HRC Fertility Launches Innovative Clinical Trial with Gameto for More Approachable IVF

LOS ANGELES, CA / ACCESS Newswire / July 9, 2025 / HRC Fertility is proud to announce its participation in a groundbreaking clinical trial evaluating…

July 9, 2025

AGFA HealthCare Achieves HITRUST I1 Certification, Demonstrating Its Commitment to and Compliance With Data Protection Standards, and Protecting Against Cybersecurity Threats

AGFA HealthCare Achieves HITRUST I1 Certification, Demonstrating Its Commitment to and Compliance With Data Protection Standards, and Protecting Against Cybersecurity Threats

HITRUST certification validates that AGFA HealthCare is operating using leading security practices to protect sensitive information. MORTSEL, BE / ACCESS Newswire / July 9, 2025…

July 9, 2025

North Shore Uranium Engages Investing News Network

North Shore Uranium Engages Investing News Network

VANCOUVER, BC / ACCESS Newswire / July 8, 2025 / North Shore Uranium Ltd. (TSX-V:NSU) (“North Shore” or the “Company“) is pleased to announce that…

July 8, 2025

Legal Dispute Arises Over Satisfied Mortgage in Queens Foreclosure Case

Legal Dispute Arises Over Satisfied Mortgage in Queens Foreclosure Case

A New York foreclosure case involving a previously satisfied mortgage led to a key Appellate Division ruling. The court upheld the rights of a third-party…

July 8, 2025

New to The Street Announces Media Coverage of BitMine Immersion Technologies Inc., Including NewsOut Video PR Integration

New to The Street Announces Media Coverage of BitMine Immersion Technologies Inc., Including NewsOut Video PR Integration

NEW YORK CITY, NEW YORK / ACCESS Newswire / July 8, 2025 / New to The Street, the award-winning national TV business show airing weekly…

July 8, 2025

Curative Health Insurance Company’s Financial Strength Rating Affirmed by AM Best for Third Consecutive Year

Curative Health Insurance Company’s Financial Strength Rating Affirmed by AM Best for Third Consecutive Year

AUSTIN, TX / ACCESS Newswire / July 8, 2025 / Curative Insurance Company is proud to announce that AM Best, the global credit rating agency…

July 8, 2025

CMG Welcomes David Schwartz, Area Sales Manager

CMG Welcomes David Schwartz, Area Sales Manager

NEW YORK CITY, NEW YORK / ACCESS Newswire / July 8, 2025 / CMG Home Loans, the retail division of well-capitalized privately held mortgage lender,…

July 8, 2025

PrivateJet.com Launches a New Era in On-Demand Luxury Air Travel

PrivateJet.com Launches a New Era in On-Demand Luxury Air Travel

MIAMI, FL / ACCESS Newswire / July 8, 2025 / PrivateJet.com (PrivateJet.com LLC), the leading domain in private aviation, has officially launched. The platform guides…

July 8, 2025

Skip Barber Racing School to Build First-Ever Racing Resort in Ixtapan de la Sal, Mexico

Skip Barber Racing School to Build First-Ever Racing Resort in Ixtapan de la Sal, Mexico

NEW YORK, NY AND IXTAPAN DE LA SAL, MEXICO / ACCESS Newswire / July 8, 2025 / Skip Barber Racing School (SBRS), widely regarded as…

July 8, 2025

CoTec Investment Mkango and Hypromag Announces First Production from Commercial-Scale Recycled Rare Earth Alloy Production in the UK

CoTec Investment Mkango and Hypromag Announces First Production from Commercial-Scale Recycled Rare Earth Alloy Production in the UK

VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / July 8, 2025 / CoTec Holdings Corp. (TSXV:CTH)(OTCQB:CTHCF) (“CoTec” or the “Company”) is pleased to note that Mkango…

July 8, 2025

New, FREE Mid-Year Real Estate Market Report From The CE Shop Offers Actionable Insights From Industry Leaders

New, FREE Mid-Year Real Estate Market Report From The CE Shop Offers Actionable Insights From Industry Leaders

The CE Shop provides the tips needed for real estate business owners, brokerages, and leaders to thrive throughout the rest of 2025 and beyond DENVER,…

July 8, 2025

Coca Access and Benefit Sharing Agreement Authorized by Peru’s National Institute of Agrarian Innovation (INIA) Supports Research Efforts of Jaguar Health and Filament Health Joint Venture, Magdalena Biosciences, into Potential Mental Health and CNS Indications of Coca

Coca Access and Benefit Sharing Agreement Authorized by Peru’s National Institute of Agrarian Innovation (INIA) Supports Research Efforts of Jaguar Health and Filament Health Joint Venture, Magdalena Biosciences, into Potential Mental Health and CNS Indications of Coca

Magdalena is focused on developing novel, natural prescription medicines derived from plants for mental health indications SAN FRANCISCO, CA / ACCESS Newswire / July 8,…

July 8, 2025

Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of  First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic Cancer

Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic Cancer

Investigator initiated exploratory clinical study being conducted in Israel pursuant to agreement with collaboration partner, PeriNess Company evaluating systemic recombinant human DNase I (DNase I)…

July 8, 2025

Brenmiller to Launch New bGen(TM) Thermal Energy Storage System for Nuclear Small Modular Reactors (SMRs) – Powering the Nuclear Resurgence

Brenmiller to Launch New bGen(TM) Thermal Energy Storage System for Nuclear Small Modular Reactors (SMRs) – Powering the Nuclear Resurgence

Nuclear power is increasingly seen as the next-generation source to support the energy demands of computing and AI infrastructure while boosting energy independence and decarbonizing…

July 8, 2025

Monogram Technologies Announces the Mandatory Conversion of 8.00% Series D Convertible Cumulative Preferred Stock

Monogram Technologies Announces the Mandatory Conversion of 8.00% Series D Convertible Cumulative Preferred Stock

AUSTIN, TEXAS / ACCESS Newswire / July 8, 2025 / Monogram Technologies Inc. (NASDAQ:MGRM) (“Monogram” or the “Company”), an AI-driven robotics company revolutionizing orthopedic surgery,…

July 8, 2025

LQR House Announces Strategic Marketing Cooperation with Montauk Distilling Co. for Cinnamon Flavored Rum

LQR House Announces Strategic Marketing Cooperation with Montauk Distilling Co. for Cinnamon Flavored Rum

Cooperation expected to drive targeted awareness and ecommerce sales to the brand through LQR House’s proprietary marketing channels MIAMI BEACH, FLORIDA / ACCESS Newswire /…

July 8, 2025

CEO Spotlight: American Rebel’s Andy Ross on Turning Patriotism into a Breakout Product

CEO Spotlight: American Rebel’s Andy Ross on Turning Patriotism into a Breakout Product

An Executive Q&A with American Rebel CEO Andy Ross, presented by Hawk Point Media NASHVILLE, TN / ACCESS Newswire / July 8, 2025 / As…

July 8, 2025

Cheech & Chong Make History at Tales of the Cocktail

Cheech & Chong Make History at Tales of the Cocktail

The comic duo’s High & Dry THC-infused seltzers mark a groundbreaking moment in the spirits industry as the first-ever cannabis beverage to sponsor the revered…

July 8, 2025

Electrovaya to Provide Battery Systems for Electrified Class 8 Trucks through Supply Agreement with Janus Electric

Electrovaya to Provide Battery Systems for Electrified Class 8 Trucks through Supply Agreement with Janus Electric

Represents Electrovaya’s foray into a new mission critical sector of heavy duty Class 8 trucks for the Australian and US markets TORONTO, ON / ACCESS…

July 8, 2025

American Critical Minerals Highlights Recent Positive Developments in Close Proximity to its Green River Potash and Lithium Project, Reinforcing the Potential of the Project

American Critical Minerals Highlights Recent Positive Developments in Close Proximity to its Green River Potash and Lithium Project, Reinforcing the Potential of the Project

Intrepid Potash continues to Increase Potash Production as Potash Prices Continue to Rise Anson Resources Builds on Successful Lithium Pilot at Green River with Commencement…

July 8, 2025

Nano One Positioned for Rising LFP Demand, Aligned with Energy Strategies & Supporting Critical Mineral Localization Efforts Worldwide

Nano One Positioned for Rising LFP Demand, Aligned with Energy Strategies & Supporting Critical Mineral Localization Efforts Worldwide

Highlights: BNEF projects global demand for LFP CAM in regions outside China to grow 5x by 2035. Nano One aligned with global leaders on critical…

July 8, 2025

Wudinna Gold Project Acquisition – Update

Wudinna Gold Project Acquisition – Update

Cobra Notice of Meeting issued; 39% voting support already confirmed HIGHLIGHTS Binding terms agreed with Cobra Resources PLC for acquisition of its 279,000oz Au South…

July 7, 2025

Unusual Machines Inc. Promotes Stacy Wright to Executive Vice President of Revenue as Company Scales U.S. Footprint and Prepares for Accelerated Growth

Unusual Machines Inc. Promotes Stacy Wright to Executive Vice President of Revenue as Company Scales U.S. Footprint and Prepares for Accelerated Growth

ORLANDO, FL / ACCESS Newswire / July 7, 2025 / Unusual Machines, Inc. (NYSE American:UMAC), a leader in drone technology and component manufacturing, has promoted…

July 7, 2025

MicroGenDX Transforms Infectious Disease Diagnostics With Innovative 24-Hour Testing Technology

MicroGenDX Transforms Infectious Disease Diagnostics With Innovative 24-Hour Testing Technology

From Days to Hours: MicroGenDX Ushers in Next-Day NGS Results ORLANDO, FLORIDA / ACCESS Newswire / July 7, 2025 / MicroGenDX, a national leader in…

July 7, 2025

Optex Systems Announces a $2.8 Million Award for Optical Sighting System

Optex Systems Announces a $2.8 Million Award for Optical Sighting System

RICHARDSON, TX / ACCESS Newswire / July 7, 2025 / Optex Systems Holdings, Inc. (NASDAQ:OPXS), a leading manufacturer of precision optical sighting systems for domestic…

July 7, 2025

West Coast Tire & Services Launches Enhanced Auto Repair Initiative in South OC

West Coast Tire & Services Launches Enhanced Auto Repair Initiative in South OC

West Coast Tire and Services is rolling out a new initiative focused on boosting customer engagement and improving service delivery in South Orange County, California….

July 7, 2025

West Coast Tire & Services Expands Auto Repair Excellence to Dana Point & Beyond

West Coast Tire & Services Expands Auto Repair Excellence to Dana Point & Beyond

West Coast Tire & Services, a well-known auto care provider located in San Juan Capistrano, California, is expanding its service area to include San Clemente….

July 7, 2025

From Chronic Back Pain to Black Diamond Runs: Dr. Jason M. Cuéllar Restores Motion with Three-Level Lumbar Disc Replacement for Endoscopic Spine Pioneer Dr. Scott Adelman

From Chronic Back Pain to Black Diamond Runs: Dr. Jason M. Cuéllar Restores Motion with Three-Level Lumbar Disc Replacement for Endoscopic Spine Pioneer Dr. Scott Adelman

Spine Surgeon Returns to Competitive Sports, Completes a Triathlon Just 8 Months After Successful Motion-Preserving Spine Surgery PALM BEACH, FL / ACCESS Newswire / July…

July 7, 2025